Do you have the therapeutic expertise I need for my project?

Do you have the therapeutic expertise I need for my project?

Simply, Yes.

We offer the guidance and specialized services to drive your programs in oncology, neuroscience, CV and metabolic, musculoskeletal, inflammation, immunology, and rare diseases.

Our goal is the same as yours: to cure disease. Over the years we have helped clients with their research and development needs in all major therapeutic areas in addition to rare disease. Our multidisciplinary, teams continuously consult in-house experts up and down the pipeline to ensure your success. We are here to support and guide you by applying our deep scientific knowledge and therapeutic insight directly to your project.

…we explain what we can do to help our client better understand… and what this means for their program.”

13+

therapeutic area scientific networks for unparalleled collaboration

275+

scientific posters presented yearly

650+

species-specific biomarker assays in multiple matrices

70+

validated neurological and rare disease animal models

450+

patient-derived xenograft (PDX) models

~50

thought-leading scientific webinars per year

Video: Modelling the Immune Response

Rhiannon Jenkinson, Director of Science at Charles River, discusses modeling the immune response.

Article: Bringing IO Together: How an Immunologist and Oncologist Collaborate in an Emerging Field

For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing novel treatments for patients.

Video: What Am I Missing?

Watch to learn how optimized cellular assays that mimic the disease state can improve translation and lower the risk of late stage clinical failures.

Eureka Blog: Fighting NASH With a New Animal Model

The Zucker Diabetic Sprague Dawley Rat: A potential game changer for metabolic disease research.

Eureka Blog: Antisense Therapies and Angelman Syndrome

The chances of finding a cure for Angelman Syndrome, a rare genetic disorder, are looking better and better.

Article: Oncology’s Fifth Pillar: Cellular Immunotherapy

In this article for GEN Genetic Engineering and Biotechnology news, our scientists explain how fine-tuned screening protocols can be used to assess cell-based cancer therapies for potency and safety, says Charles River Laboratories.

Webinar: Leveraging In Vitro and Ex Vivo Tools for Oncology Research

Patient-derived xenograft (PDX) models are a valuable instrument in oncology. In this webinar, we will show how cell-based assays performed with low passage, PDX-derived material serve as cost- and time-effective tools to select appropriate models as well as conditions for in vivo efficacy studies.

Webinar: An Open Science Approach to Developing Childhood Cancer Drugs

Childhood brain tumours are genetically distinct from adult cancers and are not a focus area for drug development. M4K Pharma is pioneering a novel open science business model and working with Charles River to address these unprecedented “high risk” targets for a fraction of the usual cost.

Poster: LPS-induced Neuroinflammation: Assay for Development of New Treatment Strategies

Neuroinflammation is linked to the progression of neurodegenerative disorders. Activated inflammatory cells of the myeloid lineage, in particular microglia, play a key role in the pathogenesis of these chronic disorders.

Poster: Use of Stem Cells and Stem Cell-Derived Neurons in Support of Drug Discovery

The advent of stem cells technologies has opened up new opportunities in drug discovery and development by providing new tools for drug screening, target identification and toxicity testing.

Web: Animal Models of Huntington’s Disease

Huntington’s disease is a fatal neurodegenerative disease that is caused by the expansion of a trinucleotide repeat (CAG). At Charles River, our team has partnered with the CHDI Foundation and industry clients to develop new therapeutic candidates that lower huntingtin protein levels via different mechanisms.

Webinar: The Bare Bones: Why the Musculoskeletal System Matters for Safety Assessment

If you’re developing anti-diabetic or gut hormone-related drugs, serotonin reuptake inhibitors, fibroblast growth agonists, or any other therapeutic targeting elements of the musculoskeletal system, it’s crucial to consider what effects these potential therapeutics can have on the system.

Infographic: Mitigate Risk with Early, Actionable Immunology Data

Immunological processes play a role in most cell interactions and diseases across all systems. From target engagement and MoA to efficacy and prediction of adverse immune reactions, immunology assays deliver data that reduces your risk of late-stage failure.

Case Study: Evaluating Multiple Vectors in a Single Eye

Currently, retinal gene therapy uses native adeno-associated virus (AAV) vectors to deliver therapeutic genetic material to the retina. See how these vector solutions are delivered near the targeted cell population via intravitreal or subretinal administration.

Webinar: The Bare Bones: Why the Musculoskeletal System Matters for Safety Assessment

If you’re developing anti-diabetic or gut hormone-related drugs, serotonin reuptake inhibitors, fibroblast growth agonists, or any other therapeutic targeting elements of the musculoskeletal system, it’s crucial to consider what effects these potential therapeutics can have on the system.

Start the Conversation